Urine biomarkers for the early detection of ovarian cancer – are we there yet?
Grayson, Kelly; Gregory, Ebony; Khan, Ghazala; Guinn, Barbara-Ann
Dr Barbara Guinn B.Guinn@hull.ac.uk
Reader in Biomedical Sciences
Ovarian cancer affects around 7500 women in the United Kingdom every year. Despite this, there is no effective screening strategy or standard treatment for ovarian cancer. If diagnosed during stage I, ovarian cancer has a 90% 5-year survival rate; however, there is usually a masking of symptoms which leads to an often late-stage diagnosis and correspondingly poor survival rate. Current diagnostic methods are invasive and consist of a pelvic examination, transvaginal ultrasonography, and blood tests to detect cancer antigen 125 (CA125). Unfortunately, surgery is often still required to make a positive diagnosis. To address the need for accurate, specific, and non-invasive diagnostic methods, there has been an increased interest in biomarkers identified through non-invasive tests as tools for the earlier diagnosis of ovarian cancer. Although most studies have focused on the identification of biomarkers in blood, the ease of availability of urine and the high patient compliance rates suggest that it could provide a promising resource for the screening of patients for ovarian cancer.
|Journal Article Type||Article|
|Journal||Biomarkers in Cancer|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Grayson, K., Gregory, E., Khan, G., & Guinn, B. (2019). Urine biomarkers for the early detection of ovarian cancer – are we there yet?. Biomarkers in Cancer, 11, https://doi.org/10.1177/1179299x19830977|
|Keywords||Biomarker; Ovarian cancer; Early detection; Diagnosis; Urine|
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
You might also like
Antigenic targets for the immunotherapy of acute myeloid leukaemia